CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphoma

Rebhun, Robert B.; Kent, Michael S.; Borrofka, S. A E B; Allstadt, Sara D.; Skorupski, Katherine A; Rodríguez, C. O.

doi:10.1111/j.1476-5829.2010.00230.x

Cited by 85 publications

(131 citation statements)

References 17 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…The short median PFI and OS, breed distribution, and incidence of hypercalcemia and mediastinal masses seen in this study are similar to previous reports 12, 13. The over‐representation of Boxers seen here has been reported in previous studies of canine T‐cell lymphoma 5, 8.…”

Section: Discussionsupporting

confidence: 90%

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Avery

Burton

Bromberek

et al. 2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundCanine T‐cell lymphoma (TCL) is conventionally considered an aggressive disease, but some forms are histologically and clinically indolent. CD4 TCL is reported to be the most common subtype of TCL. We assessed flow cytometric characteristics, histologic features when available, and clinical outcomes of CD4+ TCL to determine if flow cytometry can be used to subclassify this group of lymphomas.ObjectiveTo test the hypothesis that canine CD4+ T‐cell lymphoma (TCL) is a homogeneous group of lymphomas with an aggressive clinical course.AnimalsSixty‐seven dogs diagnosed with CD4+ TCL by flow cytometry and treated at 1 of 3 oncology referral clinics.MethodsRetrospective multivariable analysis of outcome in canine CD4+ TCL including patient characteristics, treatment, and flow cytometric features.ResultsThe majority of CD4+ TCL were CD45+, expressed low class II MHC, and exhibited an aggressive clinical course independent of treatment regimen (median survival, 159 days). Histologically, CD4+ TCL were classified as lymphoblastic or peripheral T cell. Size of the neoplastic lymphocytes had a modest effect on both PFI and survival in this group. A small number of CD4+ TCL were CD45− and class II MHC high, and exhibited an apparently more indolent clinical course (median survival not yet reached).Conclusions and Clinical ImportanceAlthough the majority of CD4+ TCL in dogs had uniform clinical and flow cytometric features and an aggressive clinical course, a subset had a unique immunophenotype that predicts significantly longer survival. This finding strengthens the utility of flow cytometry to aid in the stratification of canine lymphoma.

show abstract

Section: Discussionsupporting

confidence: 90%

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Avery

Burton

Bromberek

et al. 2014

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The CR rate was 78 per cent and the median PFS was 6.2 months, with 25 per cent progression free at 30 months (Brodsky and others 2009), compared to 24 dogs with HGTCL treated with a L-CHOP-based protocol (CR rate, 88 per cent; median PFS, 3.4 months) (Rebhun and others 2011). …”

Section: Treatmentmentioning

confidence: 99%

“…* Goodman and others (2016)** Brodsky and others (2009)*** Rebhun and others (2011)CR Complete remission 1 Rate 1 2 Rate 2…”

Section: Treatmentmentioning

confidence: 99%

Treatment of T cell lymphoma in dogs

Moore¹

2016

Veterinary Record

View full text Add to dashboard Cite

Overall, canine lymphoma remains one of the most chemotherapy-responsive cancers in the dog. In addition to the stage and the substage of disease, T cell phenotype is the most consistently important prognostic factor. T cell lymphoma (TCL) in dogs is a heterogeneous disease; dogs with a separate entity of indolent TCL can have a considerably better prognosis than dogs with other forms of lymphoma, and indolent TCL may not always require immediate treatment. In contrast, high-grade TCL is an aggressive disease, and when treated with CHOP-based protocols, dogs with this high-grade TCL have a complete remission rate as low as 40 per cent, relapse earlier and have shorter survival time than dogs with a comparable stage, high-grade B cell lymphoma. This review describes the different disease entities that comprise canine TCL, discusses prognosis for each and treatment options that appear to give the best outcomes.

show abstract

“…It was hypothesised that a polychemotherapy protocol with maintenance phase proves superior to a discontinuous protocol when conducted as a cohort study of comparable patient composition in a single institution eliminating interinstitutional variances and the disadvantage of using historic controls. Aside from protocol duration, other factors historically known to influence the outcome in canine lymphoma such as T/B-immunophenotype, stage, substage and corticosteroid pretreatment (Greenlee and others 1990, Myers and others 1997, Kiupel and others 1999, Piek and others 1999, Dobson and others 2001, Jagielski and others 2002, Sauerbrey and others 2007, Simon and others 2008, Rebhun and others 2011) were also evaluated to assess if any of these were of greater importance than the duration of therapy.…”

mentioning

confidence: 99%

Comparison of a CHOP‐LAsp‐based protocol with and without maintenance for canine multicentric lymphoma

et al. 2017

View full text Add to dashboard Cite

The recommendation to treat canine lymphoma with a discontinuous protocol is based on small case numbers and mostly historic controls. This study compares duration of first remission (DFR) and overall survival time (ST) with a discontinuous protocol to the same protocol with maintenance phase. 408 dogs were treated with a CHOP-LAsp (C=cyclophosphamide; H=hydroxydaunorubicin; O=Oncovin; P=prednisolone; LAsp=l-asparaginase)-based 28-week induction protocol. In 75 dogs (cohort 1), this was followed by a maintenance phase consisting of vincristine, chlorambucil and actinomycin-D with a total treatment duration of two years. In the subsequent 333 dogs, therapy was discontinued after induction (cohort 2). Median DFR and ST in cohort 1 were 216 and 375 days and 184 and 304 days in cohort 2. 6-Month, 1-year and 2-year survival rates in cohort 1 were 73 per cent, 50 per cent, 24 per cent and 67 per cent, 39 per cent, 21 per cent in cohort 2. There was no significant difference between the two protocols (P=0.291 for ST, P=0.071 for DFR). On multivariate analysis, corticosteroid pretreatment (P=0.005), thrombocytopenia at diagnosis (P=0.019), stage (P=0.009), substage b at relapse (P<0.001), age (P=0.002) and incomplete or unstable remission necessitating intensification of therapy (P=0.004) were negatively correlated with ST in both groups. This study supports the use of a discontinuous protocol for canine multicentric lymphoma.

show abstract

CHOP chemotherapy for the treatment of canine multicentric T‐cell lymphoma

Cited by 85 publications

References 17 publications

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Flow Cytometric Characterization and Clinical Outcome of CD4+ T‐Cell Lymphoma in Dogs: 67 Cases

Treatment of T cell lymphoma in dogs

Comparison of a CHOP‐LAsp‐based protocol with and without maintenance for canine multicentric lymphoma

Contact Info

Product

Resources

About